|
1
|
Raisz LG: Pathogenesis of osteoporosis:
concepts, conflicts, and prospects. J Clin Invest. 115:3318–3325.
2005. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Liu XH, Kirschenbaum A, Yao S and Levine
AC: Interactive effect of interleukin-6 and prostaglandin E2 on
osteoclastogenesis via the OPG/RANKL/RANK system. Ann NY Acad Sci.
1068:225–233. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Boyce BF and Xing L: Functions of
RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem
Biophys. 473:139–146. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Udagawa N, Takahashi N, Akatsu T, et al:
Origin of osteoclasts: mature monocytes and macrophages are capable
of differentiating into osteoclasts under a suitable
microenvironment prepared by bone marrow-derived stromal cells.
Proc Natl Acad Sci USA. 87:7260–7264. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kung YY, Felge U, Sarosi I, et al:
Activated T cells regulate bone loss and join destruction in
adjuvant arthritis through osteoprotegerin ligand. Nature.
402:304–309. 1999. View
Article : Google Scholar
|
|
6
|
Simonet WS, Lacey DL, Dunstan CR, et al:
Osteoprotegerin: a novel secreted protein involved in the
regulation of bone density. Cell. 89:309–319. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jacobs HS: Postmenopausal hormone
replacement therapy and breast cancer. Medscape Women’s Health.
5:E22000.
|
|
8
|
Grady D, Wenger NK, Herrington D, et al:
Postmenopausal hormone therapy increases risk for venous
thromboembolic disease. The heart and estrogen/progestin
replacement study. Ann Intern Med. 132:689–696. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rossouw JE, Anderson GL, Prentice RL, et
al Writing Group for the Women’ Health Initiative Investigators:
Risks and benefits of estrogen plus progestin in healthy
postmenopausal women: principal results From the Women’s Health
Initiative randomized controlled trial. JAMA. 288:321–333. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Luckman SP, Hughes DE, Coxon FP, et al:
Nitrogen-containing bisphosphonates inhibit the mevalonate pathway
and prevent post-translational prenylation of GTP-binding proteins,
including Ras. J Bone Miner Res. 13:581–589. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pechalova P, Bakardjiev A, Zaprianov Z, et
al: Bisphosphonate-associated osteonecrosis of the jaws – report of
three cases in Bulgaria and review of the literature. Acta Clin
Croat. 50:273–279. 2011.
|
|
12
|
Andreotti G, Méndez BL, Amodeo P, et al:
Structural determinants of salmon calcitonin bioactivity: The role
of the Leu-based amphipathic alpha-helix. J Biol Chem.
281:24193–24203. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shen Y, Li M and Wronski TJ: Calcitonin
provides complete protection against cancellous bone loss in the
femoral neck of ovariectomized rats. Calcif Tissue Int. 60:457–461.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ogawa K, Hori M, Takao R and Sakurada T:
Effects of combined elcatonin and alendronate treatment on the
architecture and strength of bone in ovariectomized rats. J Bone
Miner Metab. 23:351–358. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Reginster JY: Management of high turnover
osteoporosis with calcitonin. Bone. 13(Suppl 2): S37–S40. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Solheim LF, Rönningen H and Langeland N:
Effects of acetylsalicylic acid on heterotopic bone resorption and
formation in rats. Arch Orthop Trauma Surg. 105:142–145. 1986.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Carbone LD, Tylavsky FA, Cauley JA, et al:
Association between bone mineral density and the use of
nonsteroidal anti-inflammatory drugs and aspirin: impact of
cyclooxygenase selectivity. J Bone Miner Res. 18:1795–1802. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Vestergaard P, Hermann P, Jensen JE, et
al: Effects of paracetamol, nonsteroidal anti-inflammatory drugs,
acetylsalicylic acid and opioids on bone mineral density and risk
of fracture: results of the Danish Osteoporosis Prevention Study
(DOPS). Osteoporos Int. 23:1255–1265. 2012. View Article : Google Scholar
|
|
19
|
Kataoka T, Shinohara N, Takayama H, et al:
Concanamycin A, a powerful tool for characterization and estimation
of contribution of perforin- and Fas-based lytic pathways in
cell-mediated cytotoxicity. J Immunol. 156:3678–3686.
1996.PubMed/NCBI
|
|
20
|
Yamaza T, Miura Y, Bi Y, et al:
Pharmacologic stem cell based intervention as a new approach to
osteoporosis treatment in rodents. PLoS One. 3:e26152008.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lin SK, Kok SH, Kuo MY, et al: Sequential
expressions of MMP-1, TIMP-1, IL-6, and COX-2 genes in induced
periapical lesions in rats. Eur J Oral Sci. 110:246–253. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Frost HM and Jee WS: On the rat model of
human osteopenias and osteoporoses. Bone Miner. 18:227–236. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cui L, Wu T, Liu YY, et al: Tanshinone
prevents cancellous bone loss induced by ovariectomy in rats. Acta
Pharmacol Sin. 25:678–684. 2004.PubMed/NCBI
|
|
24
|
Van Poznak C, Cross SS, Saggese M, et al:
Expression of osteoprotegerin (OPG), TNF related apoptosis inducing
ligand (TRAIL) and receptor activator of nuclear factor κB ligand
(RANKL) in human breast tumours. J Clin Pathol. 59:56–63. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lowry F: FDA panel says to stop marketing
salmon calcitonin for osteoporosis. Medscape Medical News. March
6–2013, http://www.medscape.com/viewarticle/780323.
Accessed August 10, 2013.
|
|
26
|
Byrne P: Quality and outcomes framework
indicators for osteoporosis. Prescriber. 23:14–22. 2012. View Article : Google Scholar
|
|
27
|
de Freitas PH, Hasegawa T, Takeda S, et
al: Eldecalcitol, a second-generation vitamin D analog, drives bone
minimodeling and reduces osteoclastic number in trabecular bone of
ovariectomized rats. Bone. 49:335–342. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kanis JA, Melton LJ III, Christiansen C,
et al: The diagnosis of osteoporosis. J Bone Miner Res.
9:1137–1141. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rico H, Valencia MJ, Villa LF, et al:
Calcitonin versus clodronate in the prevention of
ovariectomy-induced osteopenia in rats. Clin Rheumatol. 19:47–50.
2000.PubMed/NCBI
|
|
30
|
Kavuncu V, Sahin S, Baydas G, et al: A
comparison of estrogen and two different doses of calcitonin in
ovariectomized rats. Yonsei Med J. 44:508–516. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Friedman AW: Important determinants of
bone strength: beyond bone mineral density. J Clin Rheumatol.
12:70–77. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
NIH Consensus Development Panel on
Osteoporosis Prevention, Diagnosis, and Therapy: Osteoporosis
prevention, diagnosis, and therapy. JAMA. 285:785–795. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Li XJ, Jee WS and Li YL: Flurbiprofen
enhances growth and cancellous and cortical bone accumulation in
rapidly growing long bones. Bone. 10:35–44. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Dempster DW, Birchman R, Xu R, et al:
Temporal changes in cancellous bone structure of rats immediately
after ovariectomy. Bone. 16:157–161. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Li M, Shen Y, Burton KW, et al: A
comparison of the skeletal effects of intermittent and continuous
administration of calcitonin in ovariectomized rats. Bone.
18:375–380. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
van der Linden JC, Homminga J, Verhaar JA
and Weinans H: Mechanical consequences of bone loss in cancellous
bone. J Bone Miner Res. 16:457–465. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zioupos P, Cook RB and Hutchinson JR: Some
basic relationships between density values in cancellous and
cortical bone. J Biomech. 41:1961–1968. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lee J and Vasikaran S: Current
recommendations for laboratory testing and use of bone turnover
markers in management of osteoporosis. Ann Lab Med. 32:105–112.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yasumizu T, Okuno T, Fukada Y and Hoshi K:
Age-related changes in bone mineral density and serum bone-related
proteins in premenopausal and postmenopausal Japanese women. Endocr
J. 47:103–109. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Trouvin AP and Goëb V: Receptor activator
of nuclear factor-κB ligand and osteoprotegerin: maintaining the
balance to prevent bone loss. Clin Interv Aging. 5:345–354.
2010.
|
|
41
|
Liu HY, Wu AT, Tsai CY, et al: The balance
between adipogenesis and osteogenesis in bone regeneration by
platelet-rich plasma for age-related osteoporosis. Biomaterials.
32:6773–6780. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Villa I, Mrak E, Rubinacci A, et al: CGRP
inhibits osteoprotegerin production in human osteoblast-like cells
via cAMP/PKA-dependent pathway. Am J Physiol Cell Physiol.
291:C529–C537. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Huebner AK, Schinke T, Priemel M, et al:
Calcitonin deficiency in mice progressively results in high bone
turnover. J Bone Miner Res. 21:1924–1934. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Chen WH, Zeng R, Lo WC, et al: The role of
the ERK1/2 pathway as an alternative to the aging-diminished cyclic
AMP pathway in calcitonin-mediated chondrogenesis in human nucleus
pulposus. Biomaterials. 33:8256–8264. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Xu J, Kauther MD, Hartl J, et al: Effects
of alpha-calcitonin gene-related peptide on osteoprotegerin and
receptor activator of nuclear factor-κB ligand expression in MG-63
osteoblast-like cells exposed to polyethylene particles. J Orthop
Surg Res. 5:832010. View Article : Google Scholar
|
|
46
|
Downey ME, Holliday LS, Aguirre JI and
Wronski TJ: In vitro and in vivo evidence for stimulation of bone
resorption by an EP4 receptor agonist and basic fibroblast growth
factor: Implications for their efficacy as bone anabolic agents.
Bone. 44:266–274. 2009. View Article : Google Scholar
|
|
47
|
Raisz LG: Potential impact of selective
cyclooxygenase-2 inhibitors on bone metabolism in health and
disease. Am J Med. 110(Suppl 3A): 43S–45S. 2001. View Article : Google Scholar : PubMed/NCBI
|
